
|Videos|November 26, 2013
Episode 11 - Personalized Medicine in CRPC
Advertisement
Episodes in this series

During this segment, the panelists explore the use of personalized medicine in castration-resistant prostate cancer.
Jeffrey D. Dunn, PharmD, MBA, and Raoul S. Concepcion, MD, explain that clinicians hope to have better data available in the future to provide definitive answers about treatment options for specific patient populations.
Dr Concepcion explains the variables that are being reviewed to help clinicians make wiser treatment decisions for their patients.
However, E. David Crawford, MD, reminds the panelists why achieving this goal will not be easy.
Advertisement
Related to this article

Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.

The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."

A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.

Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.

Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.

Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.

The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
NEI Director Highlights Pediatric Advances, AI’s Promise in Eye Care
3
GLP-1s Have Protective Benefit Against DME, Glaucoma Surgery
4
Keynote Address Tackles AI’s Role in Health Care, Eye Care
5













